ClinicalTrials.gg
RecruitingNCT07796230Updated Sep 1, 2026

Modified P200TE Data Collection

An observational study in Retina Disease, sponsored by Optos, PLC. Recruiting at 1 site in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Optos, PLC · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
22 Years and older
Sex
All
01

Study summary

Images will be collected on the modified P200TE

02

Conditions studied

  • Retina Disease
03

In context

Lead sponsor

Optos, PLC is the lead sponsor of 18 studies on the registry; 3 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants with eye disease seen at a US clinical site

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female participants 22 years of age or older who have full legal capacity to volunteer on the date the is signed

Participants who can follow the instructions by the clinical staff at the clinical site

Participants who agree to participate in the study

Participants with posterior segment eye disease. Example of pathologies may include but are not limited to Age-related macular degeneration, glaucoma, diabetic retinopathy, posterior uveitis, central serous chorioretinopathy, vein occlusion, epiretinal membrane and others as confirmed by the investigator.

Exclusion criteria

Exclusion Criteria

Participants unable to tolerate ophthalmic imaging.

Participants with ocular media not sufficiently clear to obtain acceptable images.

Unable to obtain acceptable image quality on participant.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Interventions

  • Deviceimaging device

    images captured on a modified P200TE

06

What researchers measure

Primary outcomes

  1. Number of images

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Bennett & Bloom Eye Centers
    Louisville, Kentucky 40222, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Oct 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2026
First posted
Sep 1, 2026
StartActual
Jul 29, 2026
Primary completionEst.
Oct 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07796230
Lead sponsor
Optos, PLC
Responsible party
Sponsor
First posted
Sep 1, 2026
Start date
Jul 29, 2026
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Sep 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion